Browsing Tag
Acrivon Therapeutics
3 posts
Early lung cancer responses push ACR-2316 into a broader randomized trial
ACR-2316 enters randomized expansion after durable lung cancer activity. Read how the six-tumor study could reshape Acrivon’s outlook.
Acrivon Therapeutics strengthens precision oncology pipeline with ACR-368 Phase 2b success and new AP3-enabled candidates
Find out how Acrivon Therapeutics is advancing precision oncology with positive ACR-368 Phase 2b data, EU trial expansion, and new AP3-enabled pipeline candidates.
FDA grants breakthrough device designation to Acrivon’s OncoSignature assay for endometrial cancer
Acrivon Therapeutics has secured a Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its…